N-of-One, the leading provider of clinical interpretation for precision medicine in oncology, recently announced an agreement with Mayo Clinic to provide access to clinical interpretation information to aid in highly complex molecular diagnostics.
Under the terms of the agreement, in select cases, N-of-One solutions will assist in the identification of biological and clinical knowledge, therapeutic options, and potential clinical trials for patients who undergo next generation cancer sequencing. This will help to translate state-of-the-art knowledge specifically related to individual patients’ tumors into molecularly informed, personalized treatment decisions. Mayo Clinic will use the clinical interpretation services for Mayo Medical Laboratories, a global reference laboratory operating within Mayo Clinic’s Department of Laboratory Medicine and Pathology, as well as in its Center for Individualized Medicine, which discovers and integrates the latest in genomic, molecular and clinical sciences into personalized care for each Mayo Clinic patient.
“The N-of-One team is pleased to work with the talented physicians and geneticists at Mayo Clinic,” said Chris Cournoyer, CEO of N-of-One. “With the rapidly increasing volume of clinical and scientific data, and hundreds of drugs currently in clinical trials, the task of interpreting molecular test results has become increasingly challenging. We are committed to providing scalable, cost effective genomic clinical decision support that delivers valuable analysis and interpretation of the relevant clinical data to support oncologists in making molecularly informed treatment decisions for their patients.”
Full Press Release featured on MarketWatch.